News & Events

Q&A: Symbiosis: US FDA boost at Scottish aseptic viral vector plant

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioProcess Insider, discussing US Food and Drug Administration (FDA) approval and what it means for Symbiosis in terms of meeting industry demands now and post-Brexit.

The article provides insight into the significance of US FDA accreditation, the Innovate UK grant and the challenges Brexit poses for Symbiosis and other pharma companies.

In the interview, Colin explains: “The successful completion of our first FDA inspection earlier this year positions Symbiosis perfectly to support the global market, including US biopharma clients developing viral vector products for commercial markets in particular.”

You can read the full Q&A here, via BioProcess Insider.

Get In Touch